{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive%2C+HER2+Negative+Breast+Cancer&page=2", "query": { "condition": "Hormone Receptor Positive, HER2 Negative Breast Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive%2C+HER2+Negative+Breast+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T19:11:02.552Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05262400", "title": "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors" ], "interventions": [ { "name": "PF-07220060 + PF-07104091 combination dose escalation", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + fulvestrant dose expansion", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + letrozole dose expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2022-03-14", "completion_date": "2026-08-23", "has_results": false, "last_update_posted_date": "2024-11-18", "last_synced_at": "2026-07-23T19:11:02.552Z", "location_count": 12, "location_summary": "Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05262400" }, { "nct_id": "NCT06040593", "title": "Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hormone-receptor-positive Breast Cancer", "HER2-low Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "No drug", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 927, "start_date": "2023-07-31", "completion_date": "2024-02-23", "has_results": false, "last_update_posted_date": "2024-02-26", "last_synced_at": "2026-07-23T19:11:02.552Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06040593" }, { "nct_id": "NCT06993844", "title": "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Advanced Breast Cancer" ], "interventions": [ { "name": "ETX-636 dose escalation", "type": "DRUG" }, { "name": "ETX-636 dose escalation in combination with fulvestrant", "type": "DRUG" }, { "name": "ETX-636 dose expansion in combination with fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ensem Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 233, "start_date": "2025-06-10", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-07-23T19:11:02.552Z", "location_count": 10, "location_summary": "Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06993844" }, { "nct_id": "NCT06388122", "title": "DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HER2-negative Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Metastatic Breast Cancer", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "HER2 Negative Breast Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Metastatic Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2024-04-30", "completion_date": "2031-06-15", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-07-23T19:11:02.552Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06388122" }, { "nct_id": "NCT06106477", "title": "Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Intermittent Fasting", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-07-19", "completion_date": "2026-07-15", "has_results": false, "last_update_posted_date": "2025-08-13", "last_synced_at": "2026-07-23T19:11:02.552Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06106477" }, { "nct_id": "NCT06760637", "title": "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PF-07220060", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "abemaciclib", "type": "DRUG" }, { "name": "palbociclib", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1035, "start_date": "2025-01-06", "completion_date": "2037-12-29", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-07-23T19:11:02.552Z", "location_count": 218, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06760637" }, { "nct_id": "NCT02107703", "title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 669, "start_date": "2014-07-22", "completion_date": "2027-12", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-07-23T19:11:02.552Z", "location_count": 43, "location_summary": "Jonesboro, Arkansas • Springdale, Arkansas • La Jolla, California + 36 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02107703" }, { "nct_id": "NCT05020860", "title": "Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasm", "Breast Cancer Female", "Breast Cancer Invasive", "Breast Cancer Stage II", "Breast Cancer Stage III", "Triple Negative Breast Cancer", "Hormone Receptor-positive Breast Cancer", "HER2-positive Breast Cancer", "Triple Negative Breast Neoplasms", "Estrogen Receptor-positive Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pertuzumab/Trastuzumab/Hyaluronidase-zzxf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Breast Care Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2023-04-18", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-07-23T19:11:02.552Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05020860" }, { "nct_id": "NCT01674140", "title": "S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "exemestane", "type": "DRUG" }, { "name": "goserelin acetate", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1939, "start_date": "2013-09-12", "completion_date": "2030-01", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-07-23T19:11:02.552Z", "location_count": 1455, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01674140" }, { "nct_id": "NCT06086340", "title": "Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 779, "start_date": "2023-09-29", "completion_date": "2024-01-24", "has_results": true, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-07-23T19:11:02.552Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06086340" } ] }